淋巴瘤化疗所致血小板减少症防治中国专家共识

Chinese expert consensus on prevention and treatment of chemotherapy-induced thrombocytopenia in malignant lymphoma

化疗所致血小板减少症(CIT)是淋巴瘤患者化疗后常见的不良反应,有可能导致化疗剂量降低、化疗时间延迟,甚至化疗终止,从而影响临床疗效和患者生存,并增加医疗费用。目前CIT的治疗主要包括输注血小板、重组人血小板生成素、重组人白细胞介素11等的应用。共识专家组参考了国内外有关研究和循证医学证据,在肿瘤CIT诊疗中国专家共识(2018版)基础上,提出了淋巴瘤CIT的预防和治疗方法,旨在促进临床规范合理用药,提高淋巴瘤CIT的治疗水平。

Chemotherapy-induced thrombocytopenia(CIT)is a common side effect after chemotherapy for malignant lymphoma,which may lead to the reduction of chemotherapy dose,delay of chemotherapy time,or even termination of chemotherapy,thereby affecting clinical efficacy and patient survival,and increasing medical costs.At present,CIT treatment mainly includes the application of platelet infusion,recombinant human thrombopoietin and recombinant human interleukin-11.With reference to the relevant domestic and foreign research and evidence-based medicine,and on the basis of the Chinese expert consensus on diagnosis and treatment of tumor CIT(version 2018),the consensus expert group proposed the prevention and treatment methods of CIT in malignant lymphoma,aiming to promote the clinical standard and rational drug use and improve the treatment level of CIT in malignant lymphoma.